1848239-71-3
1848239-71-3
Chemical Structure
Tivanisiran sodium
Synonym(s): SYL1001 sodium
- CAS No.: 1848239-71-3
- Formula:C361H411N141O262Na36P36
- Molecular Weight:12068.3 (free acid)
SMILES: [Tivanisiran (sodium)]
Biological Activity: Tivanisiran sodium (SYL1001 sodium) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran sodium induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran sodium alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran sodium is applicable to research related to dry eye disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tivanisiran sodium | 96.85% | Tivanisiran sodium (SYL1001 sodium) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran sodium induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran sodium alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran sodium is applicable to research related to dry eye disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Moreno-Montañés J, et al. Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018;27(4):421-426. [Content Brief]
- [2]. Ruz V, et al. Clinical Results of tivanisiran, a siRNA for the treatment of dry eye disease[J]. Investigative Ophthalmology & Visual Science, 2019, 60(9): 6738-6738.
Keywords
